Login / Signup

A non-manufacturer-sponsored, retrospective study to assess 2-year safety outcomes of the BellaGel® SmoothFine as compared with its competitors in the context of the first Korean case of a medical device fraud.

Sang Eun NamSangdal LeeYounghye ChoJae-Hong Kim
Published in: PloS one (2023)
Here, we describe preliminary 2-year safety outcomes of an implant-based augmentation mammaplasty using the BellaGel® SmoothFine in the context of the first Korean case of a medical device fraud.
Keyphrases
  • healthcare
  • soft tissue
  • type diabetes
  • insulin resistance